Ciclesonide: a novel inhaled corticosteroid for the treatment of persistent asthma – a pharmacologic and clinical profile
نویسنده
چکیده
10.2217/14750708.2.2.167 © 2 part of Inhaled corticosteroids are recommended first-line therapy for asthma of all severities. Concerns regarding local and systemic side effects can influence adherence, and subsequently, efficacy and long-term asthma control. Ciclesonide is a novel inhaled corticosteroid with an improved therapeutic margin – its efficacy is similar to that of other inhaled corticosteroids, but with a potentially better local and systemic safety profile in patients with persistent asthma. Ciclesonide is activated, mainly in the lung, to desisobutyryl-ciclesonide, the active metabolite, which, together with its other pharmacokinetic properties, contributes to its improved safety profile. Additionally, the drug is delivered through a hydrofluoroalkane metered-dose inhaler, which allows high lung deposition and delivery into the small airways. The improved therapeutic margin of ciclesonide may increase patient adherence, thereby ultimately improving asthma control.
منابع مشابه
Ciclesonide in persistent asthma: the evidence of its therapeutic value
INTRODUCTION Asthma, a respiratory disease associated with airway inflammation and hyperresponsiveness, is one of the most prevalent chronic diseases worldwide affecting both children and adults. Inhaled corticosteroids are considered to be the cornerstone of asthma management. Ciclesonide, an airway-activated inhaled corticosteroid, has been developed for the management of persistent asthma. I...
متن کاملProfile of ciclesonide for the maintenance treatment of asthma
Ciclesonide is a nonhalogenated synthetic inhaled corticosteroid (ICS) that has been approved by the US Food and Drug Administration for the treatment of all severities of persistent asthma. It is available as a hydrofluroalkane pressurized metered-dose inhaler in two strengths, 80 mcg/activation and 160 mcg/activation, with the recommenced dosage being two inhalations twice-daily. It is a prod...
متن کاملاثربخشی زنجبیل در بیماران مبتلا به آسم
Background and purpose: The goal of asthma therapy is to achieve clinical control and near normal lung functions. Many patients with moderate persistent asthma fail to achieve this goal with a low dose of inhaled corticosteroid (ÏÇS) plus long-acting β2 agonist (LÂBÂ). Ïn the present study, we have checked whether another controller medication (in the form of ginger capsule) add on to ÏÇSlow do...
متن کاملPreclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma.
Ciclesonide is a novel, inhaled corticosteroid under development for the treatment of asthma. Ciclesonide is activated to desisobutyryl-ciclesonide (des-CIC) in the lungs to provide potent anti-inflammatory activity. The investigations herein compared the activity of ciclesonide with fluticasone in animal models to assess efficacy/potency as an airway anti-inflammatory and the comparative side ...
متن کاملTreatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening.
The study addressed the question whether the novel inhaled prodrug corticosteroid ciclesonide is equally effective when inhaled in the morning compared to the evening. For this purpose a double-blind, randomized, parallel group study was initiated in which 209 asthmatic patients (forced expiratory volume in one second = 50-90% predicted) inhaled either 200 microg ciclesonide in the morning or i...
متن کامل